story of the week
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The New England Journal of Medicine
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
N. Engl. J. Med 2018 Dec 05;[EPub Ahead of Print], G von Minckwitz, CS Huang, MS Mano, S Loibl, EP Mamounas, M Untch, N Wolmark, P Rastogi, A Schneeweiss, A Redondo, HH Fischer, W Jacot, AK Conlin, C Arce-Salinas, IL Wapnir, C Jackisch, MP DiGiovanna, PA Fasching, JP Crown, P Wülfing, Z Shao, E Rota Caremoli, H Wu, LH Lam, D Tesarowski, M Smitt, H Douthwaite, SM Singel, CE GeyerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.